202半年一月份29日,乐鱼在线 (2696.HK)发出工司与亿胜生物制品企业合作定制开发的从组抗VEGF人源化单克隆表面抗原眼用打液HLX04-O进行了新西兰乐鱼在线 处理局(Therapeutic Goods Administration,TGA)的临床药理上护理应力测试备案申请,被审批于新西兰展开3期临床药理上护理科学研究探讨,拟用以湿性时间有关的性黄斑转化(wAMD)的治疗方法。该类目在新西兰的3期临床药理上护理科学研究探讨将于近几日启动服务器。
坚信根据乐鱼在线 与亿胜菌物的合作方式,HLX04-O在中国大陆区县内地、澳大利亚、欧共体、澳大利亚等国和区县的新国际多中心局临床上检验即将提高初始化,并要借助相关的的研究探讨没想到在亚洲个国和区县进行出现,被选为第五批提升批准书适用护眼相关的的症状改善的贝伐珠单抗,受益亚洲成百上千护眼症状人。中国未来,乐鱼在线 也将继续带领革新菌物保健药品的建设,要借助已然创建起的完整的革新研发团队软件平台,继续极有效率地为亚洲人作为可的压力的、功效更多的改善策划方案。
参考文献
🎐 [1] 欧阳灵艺, 邢怡桥. 抗VEGF药物剂量在湿性年轻有关于性黄斑退行中的app近展[J]. 香港国际眼科整形异物, 2020(1).
൩ [2] Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP, Mariotti SP. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004 Nov;82(11):844-51.
🎃 [3] Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106-116.
🌜 [4] Li X R , Liu J P . Recognition of anti-VEGF therapy base on the mechanism of VEGF in wet age-related macular degeneration[J]. Zhonghua Shiyan Yanke Zazhi/Chinese Journal of Experimental Ophthalmology, 2012, 30(4):289-292.
𒀰 [5] Tufail A, Patel PJ, Egan C, Hykin P, da Cruz L, Gregor Z, Dowler J, Majid MA, Bailey C, Mohamed Q, Johnston R, Bunce C, Xing W; ABC Trial Investigators. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomized double masked study. BMJ. 2010 Jun 9;340:c2459.
ꦬ [6] Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011 May 19;364(20):1897-908.
🍎 [7] Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, Reeves BC. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012 Jul;119(7):1399-411.
ꦡ [8] Kodjikian L, Souied EH, Mimoun G, Mauget-Faÿsse M, Behar -Cohen F, Decullier E, Huot L, Aulagner G; GEFAL Study Group. Ranibizumab versus Bevacizumab for Neovascular Agerelated Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial. Ophthalmology. 2013 Nov;120(11):2300-9.
🎃 [9] Krebs I, Schmetterer L, Boltz A, Told R, Vécsei-Marlovits V, Egger S, Schönherr U, Haas A, Ansari-Shahrezaei S, Binder S; MANTA Research Group. A randomized double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol. 2013 Mar;97(3):266-71.
ಌ [10] Berg K, Pedersen TR, Sandvik L, Bragadóttir R. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology. 2015 Jan;122(1):146-52.
🌺[11] Schauwvlieghe AM, Dijkman G, Hooymans JM, Verbraak FD, Hoyng CB, Dijkgraaf MG,Peto T, Vingerling JR, Schlingemann RO. Comparing the Effectiveness of Bevacizumab to Ranibizumab in Patients with Exudative Age-Related Macular Degeneration. The BRAMD Study. PLoS One. 2016 May 20;11(5):e0153052.